Kidron Miriam 4
4 · ORAMED PHARMACEUTICALS INC. · Filed Mar 18, 2026
Research Summary
AI-generated summary of this filing
Oramed (ORMP) CSO Miriam Kidron Receives RSU Award
What Happened
Miriam Kidron, Chief Scientific Officer and director of Oramed Pharmaceuticals (ORMP), received an award of 119,558 Restricted Stock Units (RSUs) reported on 2026-03-17. The grant is reported at $0.00 per unit (acquisition value $0) because these are compensation RSUs rather than an open-market purchase. Each RSU represents the right to one share of Oramed common stock upon vesting.
Key Details
- Transaction date: 2026-03-17; Form 4 filed: 2026-03-18 (timely filing).
- Transaction type/code: A — Grant / Award (RSUs).
- Amount granted: 119,558 RSUs; reported acquisition price: $0.00; reported dollar value: $0.
- Vesting: RSUs vest ratably in 8 quarterly installments beginning April 1, 2026 (per footnote).
- Post-transaction holdings: Not specified in the provided excerpt of the filing.
- No 10b5-1 plan, tax withholding, or sale noted in this transaction.
Context
This was a compensation grant (RSUs) rather than a cash purchase or sale. RSUs do not convey shares until they vest and convert into common stock, so they do not represent immediate market-selling pressure. Such awards are common for executive compensation and align future pay with stock performance; they should be interpreted as compensation, not necessarily a direct bullish signal.
Insider Transaction Report
- Award
Common Stock
[F1]2026-03-17+119,558→ 1,568,222 total
Footnotes (1)
- [F1]Represents Restricted Stock Units ("RSUs"). The RSUs will vest ratably in 8 quarterly installments beginning April 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share, of the Issuer.